Lucy Foley:從 13 歲在藥房工作到領導細胞及基因治療公司 Exmoor Pharma
From a pharmacy job at 13 to leading a cell and gene therapy firm
Lucy Foley由 13 歲在藥房工作,走到出任細胞及基因治療製造商 Exmoor Pharma 行政總裁,並分享行業擴大創新的挑戰。她曾在 CPI 協助建立英國國家生物製造中心,並領導 RNA 卓越中心的發展。她指出,業界需要善用 AI 和機器學習、擴大產量並降低成本,讓更多患者獲得關鍵藥物。
Lucy Foley. Image: Sophie Jordan Photography.
Exmoor Pharma’s Lucy Foley explores the cell and gene therapy landscape and scaling innovation.
For Lucy Foley, the CEO of cell and gene therapy manufacturer Exmoor Pharma, there was no one moment that led her to a career in the medical sector, however, exposure came quite young.
Having always held a love for science, practical and lab work, at just 13 years old she had a job in a local pharmacy, where, during quiet spells, the pharmacist would teach Foley about how medicines worked and dispensing them.
She told SiliconRepublic.com, “Nobody in my family worked in that world, so it showed me there were plenty of careers around medicine that didn’t involve becoming a doctor. That curiosity led me to the library at college, where I found chemical engineering.
“When I was interviewing for chemical engineering degrees, I came across biochemical engineering at UCL and it was a revelation. I could study biology, which was my favourite subject and still be an engineer.”
Calm under pressure
Previously, Foley was a part of CPI, where she helped to establish the UK’s National Biologics Manufacturing Centre and later led the development of the RNA Centre of Excellence as part of the UK’s Covid-19 response.
Her earlier career spanned both biochemical engineering and business, where she focused on a single goal, enabling novel therapies to scale and excel, now, she was becoming instrumental in developing a process that could almost be defined by its unpredictability.
Of establishing the RNA Centre she said, “I’m not sure I appreciated what we were living through at the time. It was long days, long nights and constant phone calls. People rang me who I had no idea had got my number, all wanting to discuss whether this could be done in the UK. It was fast and, at times, scary.
“It was also one of the most rewarding things I’ve done. We felt the work could make a difference to Covid-19, not just here but globally. Even if it didn’t, we were building infrastructure the UK had realised it needed and that would make the country more resilient in future.”
What resonated with Foley, during this time, was just how much of the workload sits outside of the manufacturing process.
She explained that it wasn’t simply creating a vaccine, but rather involved vial-filling capacity, sourcing a storage facility that could hold thousands of RNA vaccine vials at minus 70 degrees Celsius, finding a means to distribute them and locating suitable vaccination centres.
She said, “That was quite mind-blowing to think about. It reaffirmed for me that manufacturing a drug is only one part of getting it to patients. I look much further along the chain now, at everything else that has to fall into place before a product reaches a patient.”
Future care
Patient care is for Foley a key concern. Currently she works in cell and gene therapy, which often involves taking a patient’s own cells, modifying them and returning them to that same individual with the hope that they will experience a more targeted treatment or perhaps even a cure.
She said, “You treat someone once and the hope is that they stay disease-free for the rest of their life. That changes how we treat illness and it also raises big questions about how we pay for medicines, particularly in the UK.
“How we fund a one-off treatment with a lifetime of benefit will shape how medicines are developed, bought and sold in the future. At the moment, some of these processes can treat hundreds of patients and we need to be able to treat thousands.”
She finds this may also be a strong lure for young people, who perhaps received one of these therapies, to consider working in the industry themselves.
She added, “Getting there means industrialising how these therapies are made, and automation is desperately needed. As an industry we’re risk-averse and rightly so, because we’re giving medicines to people.
“But AI and machine learning are a hugely underused resource for us. We need to open our minds to how they could change the way we manufacture medicines, and I suspect the younger STEM community could teach us a thing or two.”
But the main focus she finds and the most important challenge to address is providing patients with greater access to critical medicines.
She said, “That means making these therapies in the best way possible, higher volumes and lower cost of goods, while maintaining quality. If processes can be scaled up or out to serve the markets they need to reach, more patients get treated.”
Don’t miss out on the knowledge you need to succeed. Sign up for the Daily Brief, Silicon Republic’s digest of need-to-know sci-tech news.
來源:Silicon Republic · siliconrepublic.com